Treatment of myopia

Details Treatment of myopia Treatment of myopia

2005-05-09

2010-06-01

Hartley, Michael G (Department: 1618)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S078080

Reexamination Certificate

active

07727544

ABSTRACT:
The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment and/or prevention of myopia. An activating energy source is utilized to photopolymerize or crosslink molecules in the sclera, thereby increasing the strength of the tissue. The individual is administered a crosslinking reagent or photopolymerizable molecule that becomes associated with the membrane, which is then precisely exposed to an energy source, such as light or ultrasound.

REFERENCES:
patent: 5310764 (1994-05-01), Baranowitz et al.
patent: 5352310 (1994-10-01), Natter
patent: 5410016 (1995-04-01), Hubbell et al.
patent: 5462990 (1995-10-01), Hubbell et al.
patent: 5468505 (1995-11-01), Hubbell et al.
patent: 5567435 (1996-10-01), Hubbell et al.
patent: 5573934 (1996-11-01), Hubbell et al.
patent: 5626863 (1997-05-01), Hubbell et al.
patent: 5756541 (1998-05-01), Strong et al.
patent: 5798349 (1998-08-01), Levy et al.
patent: 5844016 (1998-12-01), Sawhney et al.
patent: 5858746 (1999-01-01), Hubbell et al.
patent: 5910510 (1999-06-01), Strong et al.
patent: 5935942 (1999-08-01), Zeimer
patent: 5986043 (1999-11-01), Hubbell et al.
patent: 6059828 (2000-05-01), Peyman
patent: 6060582 (2000-05-01), Hubbell et al.
patent: 6121341 (2000-09-01), Sawhney et al.
patent: 6128525 (2000-10-01), Zeng et al.
patent: 6140314 (2000-10-01), Zeimer
patent: 6149931 (2000-11-01), Schwartz et al.
patent: 6153211 (2000-11-01), Hubbell et al.
patent: 6225303 (2001-05-01), Miller et al.
patent: 6248727 (2001-06-01), Zeimer
patent: 6267954 (2001-07-01), Abithbol et al.
patent: 6271233 (2001-08-01), Brazzell et al.
patent: 6306922 (2001-10-01), Hubbell et al.
patent: 6387977 (2002-05-01), Sawhney et al.
patent: 6461640 (2002-10-01), Hubbell et al.
patent: 6465001 (2002-10-01), Hubbell et al.
patent: 6475508 (2002-11-01), Schwartz et al.
patent: 6602975 (2003-08-01), Hubbell et al.
patent: 6632446 (2003-10-01), Hubbell et al.
patent: 6703037 (2004-03-01), Hubbell et al.
patent: 6858229 (2005-02-01), Hubbell et al.
patent: 2002/0091229 (2002-07-01), Hubbell et al.
patent: 2003/0017501 (2003-01-01), Hageman et al.
patent: 2003/0087985 (2003-05-01), Hubbell et al.
patent: 2003/0220245 (2003-11-01), Hubbell et al.
patent: 2003/0223957 (2003-12-01), Schwartz et al.
patent: 2004/0138329 (2004-07-01), Hubbell et al.
patent: 2005/0196427 (2005-09-01), Tirrell et al.
patent: 0995421 (2000-04-01), None
patent: WO 89/09034 (1989-10-01), None
patent: WO-9731033 (1997-08-01), None
patent: WO-0187560 (2001-11-01), None
patent: WO-0212350 (2002-02-01), None
patent: WO-2004004757 (2004-01-01), None
http://www.webmd.com/eye-health/tc
earsightedness-myopia-prevention (accessed Oct. 29, 2008).
English translation of WO 89/09034, Dec. 7, 2009.
Downs et al., “Viscoelastic Characterization of Peripapillary Sclera: Material Properties by Quadrant in Rabbit and Monkey Eyes,”J. Biomech. Eng., 125: 124-131, 2003.
Fisher et al., “Photoinitiated Polymerization of Biomaterials,”Annu. Rev. Mater. Res., 31: 171-81, 2001.
Goss et al.,Optometric Clinical Practice Guideline: Care of the Patient with Myopia, Reference Guide for Clinicians, © American Optometric Association, 1997.
Gottsch et al., “Hematogenous Photosensitization: A Mechanism for the Development of Aferelated Macular Degeneration,”Investigative Ophthalmology&Visual Science, 31(9): 1674-1682, 1990.
Gottsch et al., “Light-Induced Deposits in Bruch's Membrane of Protoporphyric Mice,”Arch Ophthalmol., 111: 126-129, 1993.
Green et al., “Pathologic Features of Senile Macular Degeneration,”Ophthalmology, 92(5): 615-627, 1985.
Haigis et al., “Comparison of immersion ultrasound biometry and partial coherence interferometry for introcular lens calculation according to Haigis,”Graefe's Arch. Clin. Exp. Ophthalmol., 238: 765-773, 2000.
Jin et al., “Effect of Electrostatis Interactions between Glycosaminoglycans on the Shear Stiffness of Cartilage: A Molecular Model and Experiments,”Macromolecules, 34: 8330-8339, 2001.
Kaufman, “Strenthening the Cornea,”Cornea, 23(5): 432, 2004.
Knapp et al., “Rheology of reconstituted type I collagen gel in confined compression,”J. Rheol., 41(5): 971-993, 1997.
Ratner et al., “Biomaterials: Where We have Been and Where We Are Going,”Annu. Rev. Biomed. Eng., 6: 41-75, 2004.
Spoerl et al., “Induction of Cross-Links in Corneal Tissue,”Exp. Eye Res., 66: 97-103, 1998.
St. Helen et al., “Rheology of the Human Sclera, 1. Anelastic Behavior,”Am. J. Ophthalmol., 52: 539-48, 1961.
van Hest et al., “Protein-based materials, toward a new level of structural control,”Chem. Commun., 1897-1904, 2001.
Visudyne, “Overview: Verteporfin for Injection,” www.visudyne.com, Last accessed Jan. 11, 2010.
Wollensak et al., “Riboflavin/Ultraviolet-A-induced Collagen Crosslinking for the Treatment of Keratoconus,”Am. J. Ophthalmol., 135: 620-627, 2003.
Sarker et al., “Tetraorganylborate salts as convenient precursors for photogeneration of tertiary amines”, J. Chem. Soc., Perkin Trans., 1998, 2315-2322, No. 2.
Supplementary European Search Report Issued Sep. 10, 2007 re European Application No. EP 05 74 6596.
Wollensak et al., “Collagen crosslinking of human and porcine sclera”, J Cataract Refract Surg. Mar. 2004; 689-95; vol. 30(3).

Affiliated with

Also associated with

Rating

Treatment of myopia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of myopia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of myopia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4184840